Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through data-driven insights
Health Intelligence Company
Centrellis™
Women's Health
Precision Oncology
Robust Research
Robust Research
Health Intelligence Company

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more
Centrellis™

Centrellis

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more
Women's Health

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more
Precision Oncology

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more
Biopharma

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more
Robust Research

Robust Research

Sema4’s internationally recognized research is run by world leaders in data science, network modeling, multiscale biotechnology, and genomics. We’ve published more than 1,000 peer-reviewed publications in the last five years and remain committed to making new biological discoveries.

Learn more
July 22nd, 2021

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Sema4 has announced the completion of its business combination with CM Life Sciences and will debut on Nasdaq under the ticker symbol “SMFR.”
 Read more
July 7th, 2021

Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

Jason Ryan has been appointed to Sema4’s Board of Directors. Jason brings an impressive background in finance and scaling businesses.
 Read more
June 17th, 2021

Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

Andrew Kasarskis, PhD, has joined Sema4 in the newly established role of Chief Data Officer. Dr. Kasarskis brings more than 20 years of leadership and broad experience.
 Read more
Featured In
Awards and Recognition

Back to Top
© 2021 Sema4. All rights reserved.